We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    204653
Previous Study | Return to List | Next Study

An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma (Meteor 1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02783300
Recruitment Status : Active, not recruiting
First Posted : May 26, 2016
Last Update Posted : June 28, 2022
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline

Brief Summary:
This first time in human (FTIH) open-label, dose escalation study will assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of GSK3326595 in participants with advanced or recurrent solid tumors, as well as clinical activity in participants with a subset of solid tumors and non-Hodgkin's lymphoma (NHL).

Condition or disease Intervention/treatment Phase
Neoplasms Drug: GSK3326595 Drug: Pembrolizumab Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 288 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: This will be a three-part study where Part 1 is dose escalation, including assessment of Food Effect and Relative Bioavailability, Part 2 is disease specific expansion cohorts to better characterize the clinical activity and safety profile of GSK3326595 and Part 3 is dose determination of GSK3326595 in combination with pembrolizumab.
Masking: None (Open Label)
Masking Description: This is an open label study.
Primary Purpose: Treatment
Official Title: A Phase I, Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Subjects With Solid Tumors and Non-Hodgkin's Lymphoma
Actual Study Start Date : August 30, 2016
Estimated Primary Completion Date : August 31, 2023
Estimated Study Completion Date : August 31, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arm Intervention/treatment
Experimental: Part 1: Dose Escalation, Food effect and Relative Bioavailability of Capsule formulation to Tablet
Participants will receive escalating doses of GSK3326595 until the maximum tolerated dose level is reached. The recommended phase 2 dose (RP2D) will be determined. Participants will be dosed in a fed (high-fat, high-calorie meal) and fasted state to determine the effect of food on bioavailability of GSK3326595, and will be dosed with tablet and capsule to compare two formulations of GSK3326595 (capsule versus tablet).
Drug: GSK3326595
GSK3326595 will be administered with and without food, in tablet and capsule formulation.

Experimental: Part 2: Disease-Specific Expansion cohort
Participants with triple-negative breast cancer (TNBC), metastatic transitional cell carcinoma of the urinary system (mTCC), Grade IV anaplastic astrocytoma (glioblastoma multiforme [GBM]), non-Hodgkin's lymphoma (NHL), adenoid cystic carcinoma (ACC), hormone receptor-positive adenocarcinoma of the breast (ER+BC), human papillomavirus (HPV)-positive solid tumors of any histology, and p53-wild type non-small cell lung cancer (NSCLC) will be administered GSK3326595 at the recommended phase 2 dose (RP2D) as determined in Part 1.
Drug: GSK3326595
GSK3326595 will be administered with and without food, in tablet and capsule formulation.

Experimental: Part 3: GSK3326595 in combination with pembrolizumab
Participants with selected solid tumors will be administered GSK3326595 in combination with pembrolizumab as part of this dose determination study.
Drug: GSK3326595
GSK3326595 will be administered with and without food, in tablet and capsule formulation.

Drug: Pembrolizumab
Pembrolizumab will be administered.




Primary Outcome Measures :
  1. Parts 1 and 3: Number of participants with any adverse events (AEs), serious adverse events (SAEs), withdrawal due to AEs, dose interruptions and reductions [ Time Frame: Up to approximately 2 years ]
    All AEs, SAEs and dose modifications will be collected.

  2. Part 1: Number of participants with dose limiting toxicities (DLTs) [ Time Frame: Up to 21 days ]
    An event is considered to be a DLT if the event occurs within the first 21 days of treatment and meets the dose-limiting toxicity criteria, unless it can be clearly established that the event is unrelated to treatment.

  3. Parts 1 and 3: Number of participants with clinically significant changes in laboratory parameters, vital signs, physical examination and organ-specific parameters. [ Time Frame: Up to approximately 2 years ]
    Blood and urine samples will be collected for analysis of lab parameters. Vital signs, physical examinations and organ-specific parameters will be collected at specified time points.

  4. Part 2: Participants with solid tumors (non-GBM): Overall response rate (ORR) based on Evaluation Criteria In Solid Tumors (RECIST) 1.1 [ Time Frame: Up to approximately 2 years ]
    ORR is defined as the percentage of participants achieving a confirmed complete response (CR) or partial response (PR) based on RECIST 1.1 criteria.

  5. Part 2: Participants with NHL: ORR based on Lugano criteria [ Time Frame: Up to approximately 2 years ]
    ORR is defined as the percentage of participants achieving CR or PR based on Lugano criteria.

  6. Part 2: GBM cohort: Six-month progression free survival (PFS) rate [ Time Frame: Up to 6 months ]
    PFS is defined as the percentage of participants free from radiographic progression per Response Assessment in Neuro-Oncology (RANO) criteria, or death due to any cause, for six months after starting GSK3326595.


Secondary Outcome Measures :
  1. Parts 1 and 3: Maximum observed plasma concentration (Cmax) of GSK3326595 [ Time Frame: Baseline and up to approximately 2 years ]
    Blood samples will be collected at given time points to determine the Cmax of GSK3326595.

  2. Parts 1 and 3: Area under the plasma concentration-time curve (AUC) extrapolated from time zero to infinity (AUC[0-inf]) of GSK3326595 [ Time Frame: Up to approximately 2 years ]
    Blood samples will be collected at given time points to determine the AUC (0-inf) of GSK3326595.

  3. Parts 1 and 3: AUC from time zero to the last quantifiable concentration after dosing (AUC[0-t]) of GSK3326595 [ Time Frame: Up to approximately 2 years ]
    Blood samples will be collected at given time points to determine the AUC (0-t) of GSK3326595.

  4. Parts 1 and 3: AUC over the dosing interval tau (AUC[0-tau]) of GSK3326595 [ Time Frame: Up to approximately 2 years ]
    Blood samples will be collected at given time points to determine the AUC (0-tau) of GSK3326595.

  5. Parts 1 and 3: Terminal phase half-life (t1/2) of GSK3326595 [ Time Frame: Up to approximately 2 years ]
    Blood samples will be collected at given time points to determine the half-life of GSK3326595.

  6. Parts 1 and 3: Oral clearance (CL/F) of GSK3326595 [ Time Frame: Up to approximately 2 years ]
    Blood samples will be collected at given time points to determine the CL/F of GSK3326595.

  7. Parts 1 and 3: Accumulation ratio (AR) of GSK3326595 [ Time Frame: Up to approximately 2 years ]
    Blood samples will be collected at given time points to determine the AR of GSK3326595.

  8. Parts 1 and 3: Time invariance (TI) of GSK3326595 [ Time Frame: Up to approximately 2 years ]
    Blood samples will be collected at given time points to determine the TI of GSK3326595.

  9. Part 1: Participants with solid tumors: Overall response rate (ORR) based on Evaluation Criteria In Solid Tumors (RECIST) 1.1 [ Time Frame: Up to approximately 2 years ]
    ORR is defined as the percentage of participants achieving a confirmed complete response (CR) or partial response (PR) based on RECIST 1.1 criteria.

  10. Part 3: ORR based on immune-based RECIST (iRECIST) criteria [ Time Frame: Up to approximately 2 years ]
    ORR is defined as the percentage of participants achieving confirmed CR or confirmed PR based on immune-based RECIST (iRECIST) criteria.

  11. Part 2: PFS [ Time Frame: Up to approximately 2 years ]
    Progression-free survival (PFS) is defined as the time from first dose until radiographic progression per standard criteria or death due to any cause, whichever is earlier.

  12. Part 2: ORR in participants with GBM based on Response Assessment Neuro-Oncology (RANO) Working group criteria [ Time Frame: Up to approximately 2 years ]
    ORR is defined as the percentage of participants achieving a confirmed complete response (CR) or partial response (PR) based on RANO working group criteria.

  13. Part 2: (Participants in ACC tablet cohort): Duration of Response (DOR) [ Time Frame: Up to approximately 2 years ]
    DOR is defined as the time from first evidence of response (CR or PR per RECIST 1.1) to earlier date of disease progression or death due to any cause, as determined by Investigator Assessment.

  14. Part 2: (Participants in ACC tablet cohort): Overall survival (OS) [ Time Frame: Up to approximately 2 years ]
    OS is defined as the time from first dose until death from any cause.

  15. Part 2: Number of participants with any AEs, SAEs, withdrawal due to AEs, dose reductions or delays [ Time Frame: Up to approximately 2 years ]
    All AEs, SAEs and dose modifications will be collected.

  16. Part 2: Number of participants with clinically significant changes in laboratory parameters, vital signs, physical examination and organ-specific parameters [ Time Frame: Up to approximately 2 years ]
    Blood and urine samples will be collected for analysis of lab parameters. Vital signs, physical examinations and organ-specific parameters will be collected at specified time points.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Males and females greater than or equal to (>=)18 years of age (at the time consent is obtained)
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 or 2
  • Diagnosis of non-resectable or metastatic solid malignancy (as defined in the protocol) or NHL
  • Presence of evaluable disease
  • Adequate organ function (as defined in the protocol)
  • Reproductive criteria (as defined in the protocol).

Exclusion Criteria:

  • Malignancy attributed to prior solid organ transplant
  • Leptomeningeal disease, spinal cord compression, or brain metastases that require immediate central nervous system (CNS)-specific treatment in the opinion of the Investigator (for example [e.g.], for symptomatic disease)
  • History of a second malignancy, excluding non-melanoma skin cell cancer within the last three years
  • Evidence of severe or uncontrolled systemic diseases, or serious and/or pre-existing medical or other condition that could interfere with participant's safety, obtaining informed consent or compliance to the study procedures, in the opinion of the Investigator
  • Any clinically significant gastrointestinal (GI) abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach and/or bowels.
  • Select cardiac abnormalities (as defined in the protocol)
  • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation.
  • History of optic nerve neuropathy or neuritis.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02783300


Locations
Layout table for location information
United States, Colorado
GSK Investigational Site
Denver, Colorado, United States, 80218
United States, Florida
GSK Investigational Site
Miami, Florida, United States, 33136
United States, New Jersey
GSK Investigational Site
Middletown, New Jersey, United States, 07748
United States, New York
GSK Investigational Site
Harrison, New York, United States, 10604
GSK Investigational Site
New York, New York, United States, 10065
United States, Tennessee
GSK Investigational Site
Nashville, Tennessee, United States, 37203
United States, Texas
GSK Investigational Site
Dallas, Texas, United States, 75230
GSK Investigational Site
San Antonio, Texas, United States, 78229
Canada, Alberta
GSK Investigational Site
Edmonton, Alberta, Canada, T6G 1Z2
Canada, Ontario
GSK Investigational Site
Ottawa, Ontario, Canada, K1H 8L6
GSK Investigational Site
Toronto, Ontario, Canada, M5G 1Z5
France
GSK Investigational Site
Bordeaux Cedex, France, 33076
GSK Investigational Site
Lyon Cedex 08, France, 69373
GSK Investigational Site
Villejuif cedex, France, 94805
Netherlands
GSK Investigational Site
Amsterdam, Netherlands, 1066 CX
GSK Investigational Site
Leiden, Netherlands, 2333 ZA
GSK Investigational Site
Rotterdam, Netherlands, 3015 GD
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Layout table for investigator information
Study Director: GSK Clinical Trials GlaxoSmithKline
Layout table for additonal information
Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT02783300    
Other Study ID Numbers: 204653
2016-000278-39 ( EudraCT Number )
First Posted: May 26, 2016    Key Record Dates
Last Update Posted: June 28, 2022
Last Verified: June 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: IPD for this study will be made available via the Clinical Study Data Request site.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Time Frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
Access Criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
URL: http://clinicalstudydatarequest.com
Keywords provided by GlaxoSmithKline:
GSK3326595
Solid tumor
Non-Hodgkin's lymphoma (NHL)
Urinary tract cancer
Dose escalation
Adenoid cystic carcinoma (ACC)
Non small-cell lung cancer (NSCLC)
Squamous cell carcinoma of the head and neck (HNSCC)
Melanoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Pembrolizumab
GSK-3326595
Antineoplastic Agents, Immunological
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action